Inventiva (IVA) Stock Price, News & Analysis

Company Overview

Inventiva S.A. is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva's lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial. The company expects topline trial results in Q4 2026 and, if results are positive, plans to pursue U.S. regulatory approval, with a potential commercial launch in 2028.

Inventiva was founded by former Abbott Laboratories executives and became a French public limited company in 2016. Its American Depositary Shares trade on the Nasdaq Global Market under the symbol IVA, while its ordinary shares are listed on Euronext Paris. The company is led by Chief Executive Officer Andrew Obenshain, who succeeded co-founder Frédéric Cren in October 2025.

Key Stats

• Today's Range: $3.77 to $3.99
• 50-Day Range: $2.87 to $4.86
• 52-Week Range: $2.82 to $7.29
• Volume: 2.26 million shs
• Average Volume: 2.84 million shs
• Market Capitalization: $944.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.67
• Consensus Rating: Moderate Buy

Inventiva Stock Analysis - MarketRank™

Inventiva scored higher than 59% of companies evaluated by MarketBeat, and ranked 217th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Inventiva has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Inventiva has a consensus price target of $14.67, representing about 271.3% upside from its current price of $3.95.

Amount of Analyst Coverage

Inventiva has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Inventiva are expected to decrease in the coming year, from ($0.75) to ($0.85) per share.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.36% of the float of Inventiva has been sold short.

Short Interest Ratio / Days to Cover

Inventiva has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Inventiva has recently increased by 26.92%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inventiva does not currently pay a dividend.

Dividend Growth

Inventiva does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.61

News Sentiment

Inventiva has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Inventiva this week, compared to 3 articles on an average week.

Search Interest

Only 4 people have searched for IVA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

15 people have added Inventiva to their MarketBeat watchlist in the last 30 days. This is an increase of 650% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inventiva insiders have not sold or bought any company stock.

Percentage Held by Insiders

32.00% of the stock of Inventiva is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

19.06% of the stock of Inventiva is held by institutions.

Company Calendar

• Last Earnings: 9/28/2026
• Today: 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IVA
• CIK: 1756594
• Web: www.inventivapharma.com
• Phone: 33-3-80-44-75-00
• Fax: N/A
• Employees: 77
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Inventiva: $14.67
• High Price Target: $18.00
• Low Price Target: $12.00
• Potential Upside/Downside: +271.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.90
• Current Ratio: 3.81
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $5.07 million
• Price / Sales: 186.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.22) per share
• Price / Book: -17.95

Miscellaneous

• Outstanding Shares: 239,150,000
• Free Float: 162,621,000
• Market Cap: $944.64 million
• Optionable: Optionable
• Beta: 0.76